Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Upgraded at Royal Bank Of Canada

Key Points

• Royal Bank of Canada upgraded Damora Therapeutics (NASDAQ:DMRA) to a "moderate buy" in a research note, signaling increased analyst enthusiasm.
• Analyst consensus shows 2 "Strong Buy", 4 "Buy", 1 "Hold" and 1 "Sell", with a MarketBeat average rating of "Moderate Buy" and a consensus price target of $43.40.
• DMRA opened at $24.75 with a market cap of $1.49 billion, a 52‑week range of $2.45–$38.33 and a negative P/E of -2.05, indicating the stock currently trades well below analyst targets.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) was upgraded by analysts at Royal Bank Of Canada to a "moderate buy" rating in a research note issued on Thursday,Zacks.com reports.

DMRA has been the subject of a number of other research reports. Evercore initiated coverage on Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, March 25th. They set an "outperform" rating and a $46.00 price target for the company. Zacks Research upgraded Damora Therapeutics, Inc. Common Stock to a "hold" rating in a research note on Friday, January 9th. UBS Group initiated coverage on Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. They set a "buy" rating and a $45.00 price target for the company. Leerink Partners initiated coverage on Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, January 7th. They set an "outperform" rating and a $46.00 price target for the company. Finally, Guggenheim reiterated a "buy" rating and set a $40.00 price target (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, February 17th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $43.40.

Damora Therapeutics, Inc. Common Stock Stock Performance

DMRA stock opened at $24.75 on Thursday. The company has a market capitalization of $1.49 billion, a P/E ratio of -2.05 and a beta of 1.59. Damora Therapeutics, Inc. Common Stock has a 52-week low of $2.45 and a 52-week high of $38.33. The business has a 50-day simple moving average of $27.04 and a two-hundred day simple moving average of $22.75.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

Hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $40,000. Virtu Financial LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth approximately $49,000. Two Sigma Investments LP bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth approximately $76,000. Connective Capital Management LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth approximately $100,000. Finally, Geode Capital Management LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter worth approximately $266,000. Institutional investors own 14.20% of the company's stock.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company's research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.